keyword
https://read.qxmd.com/read/38632219/robotic-biliary-stricturoplasty-and-roux-en-y-hepaticojejunostomy-after-hepatic-artery-infusion-pump-injury
#1
JOURNAL ARTICLE
Emanuel Shapera, Sharona Ross, Tara Pattilachan, Maria Christodoulou, Iswanto Sucandy
BACKGROUND: Hepatic artery infusion pump (HAIP) with floxuridine/dexamethasone and systemic chemotherapy is an established treatment regimen, which had been reported about converting 47% of patients with stage 4 colorectal liver metastasis from unresectable to resectable.1,2 To this effect, HAIP chemotherapy contributes to prolonged survival of many patients, which otherwise may not have other treatment options. Biliary sclerosis, however, is a known complication of the HAIP treatment, which occurs in approximately 5...
April 17, 2024: Annals of Surgical Oncology
https://read.qxmd.com/read/38631269/predicting-early-recurrence-after-resection-of-initially-unresectable-colorectal-liver-metastases-the-role-of-baseline-and-pre-surgery-clinical-radiological-and-molecular-factors-in-a-real-life-multicentre-experience
#2
JOURNAL ARTICLE
R Moretto, M M Germani, B Borelli, V Conca, D Rossini, P Boraschi, F Donati, L Urbani, S Lonardi, F Bergamo, K Cerma, G Ramondo, F E D'Amico, L Salvatore, G Valente, B Barbaro, F Giuliante, M Di Maio, G Masi, C Cremolini
BACKGROUND: Advances in surgical techniques and systemic treatments have increased the likelihood of achieving radical surgery and long-term survival in metastatic colorectal cancer (mCRC) patients with initially unresectable colorectal liver metastases (CRLMs). Nonetheless, roughly half of the patients resected after an upfront systemic therapy experience disease relapse within 6 months from surgery, thus leading to the question whether surgery is actually beneficial for these patients...
April 16, 2024: ESMO Open
https://read.qxmd.com/read/38615197/multicenter-evaluation-of-the-safety-and-efficacy-of-selective-internal-radiation-therapy-with-yttrium-90-resin-microspheres-in-taiwan-data-from-the-resin-registry
#3
JOURNAL ARTICLE
Rheun-Chuan Lee, Po-Chin Liang, Huei-Lung Liang, Yung-Fang Chen, Chun-Yen Yu, Pin-Nan Cheng, Chien-Fu Hung, Cheng-Yuan Hsia, Hsueh-Chou Lai, Ming-Chih Ho, Yu-Fan Cheng, Yi-Sheng Liu, Yee Chao, Chien-Hung Chen
BACKGROUND AND AIM: The REgistry of Selective Internal radiation therapy in AsiaNs (RESIN) was a multicenter, single-arm, prospective, observational study of 90 Y resin microspheres in patients with hepatocellular carcinoma (HCC) or metastatic colorectal cancer (mCRC) from Taiwan. RESIN is the first real-life clinical study of this therapy in an Asian cohort. Study objectives were to evaluate the safety and efficacy of 90 Y resin microspheres. METHODS: Adults with HCC or mCRC scheduled to receive SIRT with 90 Y resin microspheres were included...
April 13, 2024: Journal of Gastroenterology and Hepatology
https://read.qxmd.com/read/38612832/lectin-based-immunophenotyping-and-whole-proteomic-profiling-of-ct-26-colon-carcinoma-murine-model
#4
JOURNAL ARTICLE
Anna Faragó, Ágnes Zvara, László Tiszlavicz, Éva Hunyadi-Gulyás, Zsuzsanna Darula, Zoltán Hegedűs, Enikő Szabó, Sára Eszter Surguta, József Tóvári, László G Puskás, Gábor J Szebeni
A murine colorectal carcinoma (CRC) model was established. CT26 colon carcinoma cells were injected into BALB/c mice's spleen to study the primary tumor and the mechanisms of cell spread of colon cancer to the liver. The CRC was verified by the immunohistochemistry of Pan Cytokeratin and Vimentin expression. Immunophenotyping of leukocytes isolated from CRC-bearing BALB/c mice or healthy controls, such as CD19+ B cells, CD11+ myeloid cells, and CD3+ T cells, was carried out using fluorochrome-labeled lectins...
April 4, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38608150/hepatic-arterial-infusion-pump-chemotherapy-combined-with-systemic-chemotherapy-for-borderline-resectable-and-unresectable-colorectal-liver-metastases-phase-ii-feasibility-study
#5
JOURNAL ARTICLE
Myrtle F Krul, Niels F M Kok, Harun Osmani, Florian E Buisman, Bas Groot Koerkamp, Dirk J Grunhagen, Cornelis Verhoef, Bianca Mostert, Petur Snaebjornsson, Bram Westerink, Elisabeth G Klompenhouwer, Maarten L Donswijk, Theo J M Ruers, Joeri A J Douma, Nico van Blijderveen, T Peter Kingham, Michael I D'Angelica, Nancy E Kemeny, Karen Bolhuis, Tineke E Buffart, Koert F D Kuhlmann
BACKGROUND: Hepatic arterial infusion pump chemotherapy combined with systemic chemotherapy (HAIP-SYS) for liver-only colorectal liver metastases (CRLMs) has shown promising results but has not been adopted worldwide. This study evaluated the feasibility of HAIP-SYS in the Netherlands. METHODS: This was a single-arm phase II study of patients with CRLMs who received HAIP-SYS consisting of floxuridine with concomitant systemic FOLFOX or FOLFIRI. Main inclusion and exclusion criteria were borderline resectable or unresectable liver-only metastases, suitable arterial anatomy and no previous local treatment...
April 3, 2024: British Journal of Surgery
https://read.qxmd.com/read/38568358/propensity-score-matched-outcomes-of-resection-of-stage-iv-primary-colon-cancer-with-and-without-simultaneous-resection-of-liver-metastases
#6
JOURNAL ARTICLE
Sameh Hany Emile, Nir Horesh, Zoe Garoufalia, Rachel Gefen, Peige Zhou, Steven D Wexner
There is controversy in the best management of colorectal cancer liver metastasis (CLM). This study aimed to compare short-term and survival outcomes of simultaneous resection of CLM and primary colon cancer compared to resection of only colon cancer. This retrospective matched cohort study included patients from the National Cancer Database (2015-2019) with stage IV colon adenocarcinoma and synchronous liver metastases who underwent colectomy. Patients were divided into two groups: colectomy-only (resection of primary colon cancer only) and colectomy-plus (simultaneous resection of primary colon cancer and liver metastases)...
April 3, 2024: Updates in Surgery
https://read.qxmd.com/read/38534000/microwave-coagulation-for-liver-metastases
#7
REVIEW
Dawid Storman, Mateusz J Swierz, Jerzy W Mitus, Michal Pedziwiatr, Ning Liang, Robert Wolff, Malgorzata M Bala
BACKGROUND: Liver metastases (i.e. secondary hepatic malignancies) are significantly more common than primary liver cancer. Long-term survival after radical surgical treatment is approximately 50%. For people in whom resection for cure is not feasible, other treatments must be considered. One treatment option is microwave coagulation utilising electromagnetic waves. It involves placing an electrode into a lesion under ultrasound or computed tomography guidance. OBJECTIVES: To evaluate the beneficial and harmful effects of microwave coagulation versus no intervention, other ablation methods, or systemic treatments in people with liver metastases regardless of the location of the primary tumour...
March 27, 2024: Cochrane Database of Systematic Reviews
https://read.qxmd.com/read/38531974/exploring-the-potential-of-ziziphus-nummularia-and-luteolin-7-o-glucoside-as-tubulin-inhibitors-in-cancer-therapy-and-survival
#8
JOURNAL ARTICLE
Sahar Saleh Alghamdi, Sara Abdulaziz Alghashem, Rizwan Ali, Arwa Alsubait, Rasha Saad Suliman, Afrah E Mohammed, Zeyad Alehaideb, Raghad Abdullah Alshafi, Allulu Yousef Alturki, Ishrat Rahman
Cancer is responsible for approximately 10 million deaths worldwide, with 70% of the deaths occurring in low- and middle-income countries; as such safer and more effective anti-cancer drugs are required. Therefore, the potential benefits of Ziziphus nummularia and Ziziphus spina-christi as sources of anti-cancer agents were investigated. Z. nummularia and Z. spina-christi extracts were prepared using chloroform, ethanol, ethyl acetate, and water. The extracts' anti-cancer properties were determined using the MTT Cell Viability Assay in four cancer cell lines: breast (KAIMRC2 and MDA-MB-231), colorectal (HCT8), and liver (HepG2)...
March 26, 2024: Scientific Reports
https://read.qxmd.com/read/38513142/chemotherapy-induced-pneumatosis-intestinalis-followed-by-hepatic-portal-venous-gas-a-case-report
#9
JOURNAL ARTICLE
WenJun Pan, Shuai Xiang, Junhao Zhang, Yuan Gao, Shanglong Liu
Pneumatosis intestinalis (PI) is a rare disease, and there are many theories about its pathogenesis. Hepatic portal venous gas (HPVG), is thought to occur secondary to intramural intestinal gas emboli migrating through the portal venous system via the mesenteric veins. PI accompanied by HPVG is usually a sign of bowel ischaemia and is associated with a high mortality rate. We report here, a patient with liver metastases from colorectal cancer who developed PI followed by HPVG after treatment with 5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6)...
March 2024: Journal of International Medical Research
https://read.qxmd.com/read/38482249/immune-checkpoint-blockade-induced-sarcoid-like-reaction-mimicking-progression-of-disease-in-a-patient-with-microsatellite-instable-colorectal-cancer-case-report-and-review-of-the-literature
#10
Fergus Keane, Elizabeth Yogiaveetil, Brie Kezlarian, Maria Lagratta, Neil H Segal, Ghassan Abou-Alfa, Eileen M O'Reilly, Leonard Saltz, Imane El Dika
BACKGROUND: Oncologists are prescribing checkpoint inhibitors with greater frequency, and an awareness of and ability to recognize immune-related adverse events (irAEs) is a key part of the safe administration of these drugs. CASE DESCRIPTION: Herein, we report the case of a 26-year-old male diagnosed with de novo metastatic right-sided colon cancer to the liver, with tumor immunohistochemistry demonstrating loss of MSH2 and MSH6 , and a pathogenic mutation in MSH2 identified on germline testing, consistent with Lynch Syndrome...
February 29, 2024: Journal of Gastrointestinal Oncology
https://read.qxmd.com/read/38473290/circulating-tumor-dna-profiling-in-liver-transplant-for-hepatocellular-carcinoma-cholangiocarcinoma-and-colorectal-liver-metastases-a-programmatic-proof-of-concept
#11
JOURNAL ARTICLE
Hanna Hong, Chase J Wehrle, Mingyi Zhang, Sami Fares, Henry Stitzel, David Garib, Bassam Estfan, Suneel Kamath, Smitha Krishnamurthi, Wen Wee Ma, Teodora Kuzmanovic, Elizabeth Azzato, Emrullah Yilmaz, Jamak Modaresi Esfeh, Maureen Whitsett Linganna, Mazhar Khalil, Alejandro Pita, Andrea Schlegel, Jaekeun Kim, R Matthew Walsh, Charles Miller, Koji Hashimoto, David Choon Hyuck Kwon, Federico Aucejo
INTRODUCTION: Circulating tumor DNA (ctDNA) is emerging as a promising, non-invasive diagnostic and surveillance biomarker in solid organ malignancy. However, its utility before and after liver transplant (LT) for patients with primary and secondary liver cancers is still underexplored. METHODS: Patients undergoing LT for hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), and colorectal liver metastases (CRLM) with ctDNA testing were included. CtDNA testing was conducted pre-transplant, post-transplant, or both (sequential) from 11/2019 to 09/2023 using Guardant360, Guardant Reveal, and Guardant360 CDx...
February 25, 2024: Cancers
https://read.qxmd.com/read/38458023/histologic-transformation-of-rectal-adenocarcinoma-to-choriocarcinoma-after-surgery-and-chemotherapy-a-rare-case-report-and-review-of-the-literature
#12
Juan Zhong, Lei Yang
INTRODUCTION AND IMPORTANCE: Choriocarcinoma is a rapidly progressive, widely metastatic, β-human chorionic gonadotropin (β-hCG)-secreting malignant tumor originating from trophoblast cells. Most choriocarcinomas are pregnancy-related. Choriocarcinoma of nonpregnant origin is very rare. CASE PRESENTATION: A 60-year-old woman underwent abdominopelvic resection (APR) for low rectal cancer in May 2020. Postoperative pathological findings showed a poorly differentiated adenocarcinoma...
March 6, 2024: International Journal of Surgery Case Reports
https://read.qxmd.com/read/38445460/personalized-circulating-tumor-dna-monitoring-improves-recurrence-surveillance-and-management-after-curative-resection-of-colorectal-liver-metastases-a-prospective-cohort-study
#13
JOURNAL ARTICLE
Yaqi Li, Jing Xu, Xiang Hu, Yikuan Chen, Fangqi Liu, Yun Chen, Xiaoji Ma, Qiduo Dong, Lei Sun, Shaobo Mo, Long Zhang, Xingfeng He, Shanyou Tong, Huizi Wu, Wenhua Li, Sanjun Cai, Shida Zhu, Qi Pan, Junjie Peng
BACKGROUND: Approximately 60% of patients with CRLM experience relapse within 2 years after radical resection, previous studies have proven that repeat local treatment (LT) could prolong survival, however, it is difficult to seize the window for LT due to the lack of a high-sensitive surveillance method. In this study, we aim to examine the value of longitudinal circulating tumor DNA (ctDNA) in guiding adjuvant chemotherapy (ACT), optimizing clinical surveillance strategy, and thereby improving CRLM outcomes...
March 4, 2024: International Journal of Surgery
https://read.qxmd.com/read/38374403/multicenter-randomized-phase-ii-study-on-s-1-and-oxaliplatin-therapy-as-an-adjuvant-after-hepatectomy-for-colorectal-liver-metastases-ycog1001
#14
JOURNAL ARTICLE
Mayumi Ozawa, Jun Watanabe, Atsushi Ishibe, Koki Goto, Yoshiro Fujii, Kazuya Nakagawa, Yusuke Suwa, Hirokazu Suwa, Hidenobu Masui, Mitsutaka Sugita, Yasuhisa Mochizuki, Shigeru Yamagishi, Seiji Hasegawa, Yuki Homma, Masashi Momiyama, Takafumi Kumamoto, Ryusei Matsuyama, Kazuhisa Takeda, Masataka Taguri, Itaru Endo
PURPOSE: The high recurrence rate of colorectal cancer liver metastasis (CRCLM) after surgery remains a crucial problem. However, adjuvant chemotherapy after hepatectomy for CRCLM has not yet been established. This study evaluated the efficacy of adjuvant therapy with S-1 and oxaliplatin (SOX). METHODS: In a multicenter, randomized, phase II study, patients undergoing curative resection of CRCLM were randomly enrolled in a 1:1 ratio to either the low- or high-dose group...
February 19, 2024: Cancer Chemotherapy and Pharmacology
https://read.qxmd.com/read/38368862/hepatic-artery-infusion-chemotherapy-for-primary-and-secondary-malignancies-of-the-liver-state-of-the-art-and-current-high-level-evidence
#15
REVIEW
Christoph Kuemmerli, Viviane Hess, Philipp Dutkowski, Stefanie Sinz, Ulf Kessler, Gabriel F Hess, Adrian T Billeter, Beat P Müller-Stich, Otto Kollmar, Philip C Müller
Background Hepatic artery infusion chemotherapy (HAI) has been proposed as a valuable adjunct for multimodal therapy of primary and secondary liver malignancies. This review provides and overview of the currently available evidence of HAI, taking into account tumor response and long-term oncologic outcome. Summary In colorectal liver metastases (CRLM), HAI in combination with systemic therapy leads to high response rates (85-90%) and conversion to resectablity in primary unresectable disease in up to 50%. HAI in combination with systemic therapy in CRLM in the adjuvant setting shows promising long-term outcomes with up to 50% 10-year survival in a large, non-randomized single center cohort...
February 16, 2024: Pharmacology
https://read.qxmd.com/read/38350888/alliance-for-clinical-trials-in-oncology-alliance-trial-a022101-nrg-gi009-a-pragmatic-randomized-phase-iii-trial-evaluating-total-ablative-therapy-for-patients-with-limited-metastatic-colorectal-cancer-evaluating-radiation-ablation-and-surgery-erasur
#16
JOURNAL ARTICLE
Kathryn E Hitchcock, Eric D Miller, Qian Shi, Jesse G Dixon, Sepideh Gholami, Sarah B White, Christina Wu, Christopher C Goulet, Manju George, Kyung-Wook Jee, Chadwick L Wright, Rona Yaeger, Ardaman Shergill, Theodore S Hong, Thomas J George, Eileen M O'Reilly, Jeffrey A Meyerhardt, Paul B Romesser
BACKGROUND: For patients with liver-confined metastatic colorectal cancer (mCRC), local therapy of isolated metastases has been associated with long-term progression-free and overall survival (OS). However, for patients with more advanced mCRC, including those with extrahepatic disease, the efficacy of local therapy is less clear although increasingly being used in clinical practice. Prospective studies to clarify the role of metastatic-directed therapies in patients with mCRC are needed...
February 13, 2024: BMC Cancer
https://read.qxmd.com/read/38335990/intraoperative-contrast-enhanced-ultrasound-has-an-outcome-relevant-impact-on-surgery-of-primary-and-metastatic-liver-lesions
#17
Florian Bitterer, Andreas Bauer, Gunther Glehr, Stefan Brunner, Katharina Schmidt, Hans Jürgen Schlitt, Ernst Michael Jung, Christina Hackl
PURPOSE: Complete resection of the affected tissue remains the best curative treatment option for liver-derived tumors and colorectal liver metastases. In addition to preoperative cross-sectional imaging, contrast-enhanced intraoperative ultrasound (CE-IOUS) plays a crucial role in the detection and localization of all liver lesions. However, its exact role is unclear. This study was designed to evaluate the clinical and oncological impact of using CE-IOUS in the surgical treatment of these diseases...
February 9, 2024: Ultraschall in der Medizin
https://read.qxmd.com/read/38333370/dabrafenib-and-trametinib-administration-in-patients-with-braf-v600e-r-or-non-v600-braf-mutated-advanced-solid-tumours-believe-ncch1901-a-multicentre-open-label-and-single-arm-phase-ii-trial
#18
JOURNAL ARTICLE
Tatsunori Shimoi, Kuniko Sunami, Makoto Tahara, Satoshi Nishiwaki, Shota Tanaka, Eishi Baba, Masashi Kanai, Ichiro Kinoshita, Hidekazu Shirota, Hideyuki Hayashi, Naohiro Nishida, Toshio Kubo, Nobuaki Mamesaya, Yayoi Ando, Natsuko Okita, Taro Shibata, Kenichi Nakamura, Noboru Yamamoto
BACKGROUND: BRAF V600 mutations are common in melanoma, thyroid, and non-small-cell lung cancers. Despite dabrafenib and trametinib being standard treatments for certain cancers, their efficacy across various solid tumours remains unelucidated. The BELIEVE trial assessed the efficacy of dabrafenib and trametinib in solid tumours with BRAF V600E/R or non-V600 BRAF mutations. METHODS: Between October 1, 2019, and June 2022, at least 50 patients with measurable and seven without measurable diseases examined were enrolled in a subcohort of the BELIEVE trial (NCCH1901, jRCTs031190104)...
March 2024: EClinicalMedicine
https://read.qxmd.com/read/38329517/-liver-transplantation-for-treatment-of-nonresectable-primary-and-secondary-liver-malignancies-hepatocellular-and-cholangiocellular-carcinomas-and-colorectal-liver-metastases
#19
REVIEW
Markus Guba, Jens Werner
BACKGROUND: With the increasing efficacy of systemic therapy, liver transplantation plays an important role not only for hepatocellular carcinoma (HCC) but also for nonresectable intrahepatic cholangiocellular carcinoma (iCC), perihilar cholangiocellular carcinoma (phCC) and colorectal liver metastases (CRLM). AIM: To review the current state of knowledge regarding the indications, patient selection and expected outcomes of liver transplantation for HCC, iCC, phCC and CRLM...
February 8, 2024: Chirurgie (Heidelb)
https://read.qxmd.com/read/38326045/-analysis-of-the-experience-and-procedural-complications-of-trans-radial-access-versus-trans-femoral-access-for-hepatic-arterial-perfusion-chemotherapy-in-patients-with-advanced-hepatic-malignancies-a-retrospective-study
#20
JOURNAL ARTICLE
T Y Lyu, M Li, J A He, Q F Sun, L Wang, H Qin, H P Yu
Objective: To analyze the differences between trans-radial access (TRA) and trans-femoral access (TFA) in hepatic arterial perfusion chemotherapy (HAIC) in terms of patient experience, postoperative complications, and patient preferences; explore whether TRA in HAIC is associated with better patient experience and compliance; and determine whether it is safer than TFA. Methods: The study was a retrospective cohort study of patients with advanced hepatocellular carcinoma and liver metastases from colorectal cancer treated with HAIC...
February 1, 2024: Zhonghua Nei Ke za Zhi [Chinese Journal of Internal Medicine]
keyword
keyword
61684
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.